Tubulin-based dual-target compounds and protein degraders for cancer therapy-An updated review (2021-present)

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Simultaneous targeting of microtubule dynamics and other carcinogenic pathways is a validated anticancer strategy.
• Tubulin-based dual-target compounds enhance antitumor efficacy, overcome drug resistance, and minimize side effects.
• Recent research has focused on developing novel compounds with improved therapeutic profiles.

Purpose of the Study:

• To review tubulin-based dual-target compounds developed in the last five years.
• To analyze their target selection, design strategies, structure-activity relationships, and anticancer properties.
• To summarize emerging targeted protein degraders and discuss future development challenges.

Main Methods:

• Literature review of scientific publications from the past five years.
• Analysis of compound design, target engagement, and structure-activity relationships.
• Evaluation of preclinical and clinical data on anticancer efficacy and safety.

Main Results:

• Numerous tubulin-based dual-target compounds have been developed with significant antitumor activity.
• Emerging targeted protein degraders show promise for enhanced cancer treatment.
• Structure-activity relationship analyses guide the design of more potent and selective compounds.

Conclusions:

• Tubulin-based dual-target compounds represent a valuable class of anticancer agents.
• Future research should focus on overcoming development challenges and exploring novel therapeutic modalities.
• Continued innovation in compound design and targeted protein degradation holds significant potential for cancer therapy.